<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131388</url>
  </required_header>
  <id_info>
    <org_study_id>AMH 2.7.1</org_study_id>
    <nct_id>NCT03131388</nct_id>
  </id_info>
  <brief_title>Clinical Performance Evaluation of AMH Assay</brief_title>
  <official_title>Clinical Performance Evaluation of AMH Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beckman Coulter, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beckman Coulter, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Access AMH Assay is an in vitro diagnostic assay intended as an aid for fertility
      assessment. The purpose of the study is to evaluate the clinical performance of the Access
      AMH Assay in the intended use population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      same as brief summary
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of AMH as an aid for fertility assessment</measure>
    <time_frame>Day 2 to 4 of menstrual cycle</time_frame>
    <description>Comparison of AMH levels in women at different levels of AFC to aid in assessing ovarian reserve</description>
  </primary_outcome>
  <enrollment type="Actual">277</enrollment>
  <condition>Anti-Mullerian Hormone</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Access AMH Assay</intervention_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult women presenting to fertility clinics for fertility assessment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥ 21 and &lt; 46 years of age

          -  Regular menstrual cycle

          -  Both ovaries present

        Exclusion Criteria:

          -  Evidence of PCOS

          -  Confirmed ovarian endometrioma

          -  Ovarian surgery prior to enrollment

          -  Being treated for cancer

          -  Hormonal contraceptive use prior to enrollment

          -  Currently pregnant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Fred Siebert</last_name>
    <role>Study Director</role>
    <affiliation>Beckman Coulter</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BRI</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSMG</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RAD</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WRMG</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vios Fertility</name>
      <address>
        <city>Swansea</city>
        <state>Illinois</state>
        <zip>62226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BIVF</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mainline Fertility</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARE</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CORM</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PNWF</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Ovo</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

